ProfileGDS5678 / 1452469_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 74% 75% 73% 74% 72% 74% 67% 67% 77% 78% 76% 77% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8406674
GSM967853U87-EV human glioblastoma xenograft - Control 24.9106174
GSM967854U87-EV human glioblastoma xenograft - Control 34.9093175
GSM967855U87-EV human glioblastoma xenograft - Control 44.7529473
GSM967856U87-EV human glioblastoma xenograft - Control 54.8967774
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5060972
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7471974
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0440667
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0975367
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3317377
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3314478
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0857176
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2298677
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2914477